Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

Li, Jing; Shao, Jingjing; Zhang, Xunlei; Chen, Xin; Zhao, Wei; Qian, Hongyan; Cui, Xiaopeng; Jiang, Xiaohui

doi:10.1155/2020/8781674

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated SII index scores indicate elevated platelets and neutrophils, and decreased lymphocytes. CRC patients are prone to infection, recurrence, or metastasis after surgery, which ultimately leads to a poor prognosis, and previous studies have confirmed that an increased SII index score is the main risk factor for the poor postoperative prognosis of CRC patients, which supports the findings of this study ( 16 - 20 ). However, compared to previous studies, this study is somewhat innovative; we did not find any other study that explored the relationship between the SII index and postoperative infectious complications in CRC patients, and this study confirmed that an increased SII index score indicates an increased incidence of postoperative infectious complications.…”

Section: Discussionsupporting

confidence: 91%

“…In patients with malignant tumors, neutrophils are inflammatory cells that indicate that the patient's systemic level of inflammation is increased, which is conducive to the local tissue angiogenesis of tumors, which in turn promotes the proliferation and metastasis of CRC cells (13). Additionally, this systemic inflammation also promotes an increase in intestinal permeability, which in turn leads to the studies have confirmed that an increased SII index score is the main risk factor for the poor postoperative prognosis of CRC patients, which supports the findings of this study (16)(17)(18)(19)(20). However, compared to previous studies, this study is somewhat innovative; we did not find any other study that explored the relationship between the SII index and postoperative infectious complications in CRC patients, and this study confirmed that an increased SII index score indicates an increased incidence of postoperative infectious complications.…”

Section: Discussionsupporting

confidence: 87%

“…A study in China showed that the incidence of postoperative infectious complications in patients with CRC was as high as 16% (3). Similarly, a foreign study showed that the incidence of postoperative infectious complications in patients with CRC was as high as 16.59% (4). Postoperative complications can lead to increased recurrence and mortality; moreover, Chen et al showed that in patients with CRC liver metastases, postoperative infectious complications were associated with worse progression-free survival (PFS) and overall survival (5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Feng¹,

Xu²,

Lin³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract. Surgery is the main way to cure CRC, but the postoperative complication rate and recurrence rate remain high. The systemic immune-inflammation (SII) index reflects a patient's systemic inflammatory state and immune state. Postoperative recurrence and the occurrence of complications are closely related to the inflammatory state and immune state. Thus, the SII index may have some value in predicting postoperative complications and the long-term prognosis of CRC patients, but relevant studies are currently lacking. The present study sought to examine the effect of the SII index on the postoperative complications and long-term prognosis of patients with CRC.Methods: From January 2014 to January 2017, the data of 440 patients with CRC who had been admitted to the Affiliated Hospital of Guangdong Medical University were retrospectively collected, and the patients were equally divided into the high and the low SII groups according to their preoperative SII index levels.The postoperative complication rate and postoperative progression-free survival (PFS) and mortality between the 2 groups were compared.Results: Compared to the low SII group, the incidence of postoperative infection in the high SII group was significantly increased (15.45% vs. 9.09%, P=0.042), mortality was significantly increased at 5 years postoperatively (20.91% vs. 7.27%, P<0.001), and PFS was significantly shortened (P<0.001). The SII index had certain predictive value for postoperative infection in CRC patients, and the area under the curve (AUC) was 0.645 [95% confidence interval (CI): 0.559-0.731, P=0.001]. The SII index also had certain predictive value for the progression of CRC patients within 5 years of surgery, and the AUC was 0.670 (95% CI: 0.610-0.729, P<0.001). Additionally, the SII index had certain predictive value for death within 5 years of surgery in patients with CRC, and the AUC was 0.660 (95% CI: 0.593-0.726, P<0.001). CRC patients with postoperative infection had a significantly shorter PFS period than those who did not develop postoperative infection (P=0.029). Conclusions:The SII index has certain predictive value for the diagnosis of postoperative infectious complications and the long-term prognosis of CRC patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Feng¹,

Xu²,

Lin³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Recently, it has been reported that the SII sore is of prognostic value in many malignant tumor types including hepatocellular carcinoma [ 37 ], gastric cancer [ 38 ], colorectal cancer [ 39 ], and urological and gynecological tumors [ 13 , 40 ]. Given that RCC is an inflammatory disease, the investigation of the SII score seems to be of particular interest in patients treated with immune checkpoint inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Stühler¹,

Herrmann²,

Rausch³

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the predictive and prognostic value of the systemic immune-inflammation index (SII) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab. Methods: This retrospective study included forty-nine mRCC patients treated with first-line ipilimumab plus nivolumab at the Department of Urology of the University of Tuebingen, Germany. SII was assessed before starting ipilimumab plus nivolumab therapy at the time of first imaging and at tumor progression. Optimal SII cut-off was stratified by ROC-analysis. Univariable and multivariable Cox regression analyses were used to evaluate the predictive and prognostic value of SII. Results: Optimal SII cut-off was 788. Twenty-nine/forty-nine patients had high SII (≥788) before initiation of ipilimumab plus nivolumab. High SII was an independent prognostic factor for worse progression-free (HR 2.70, p = 0.014) and overall survival (HR 10.53, p = 0.025). The clinical benefit rate was higher for patients with low SII if compared to high SII (80% vs. 32.1%). An increase in SII > 20% from baseline after twelve weeks of therapy was associated with progression at first imaging (p = 0.003). Conclusions: SII is both prognostic and predictive and could refine decision making in patients with unclear imaging on therapy with ipilimumab plus nivolumab.

show abstract

“…The SII has been reported as a useful prognostic indicator in many solid tumors, including gallbladder ( 31 ), pancreatic ( 13 ), and colorectal cancer ( 32 ), as well as in intrahepatic cholangiocarcinoma ( 33 ). Studies have investigated the association between SII and survival outcomes in patients with RCC ( 18 – 25 , 29 , 30 ); however, the results remain controversial.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Jin¹,

Yuan²,

Yuan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe systemic immune-inflammation index (SII) is a hematological parameter based on neutrophil, platelet, and lymphocyte counts. Studies that have investigated the prognostic value of SII in patients with renal cell carcinoma (RCC) have reported controversial results. In this study, we systematically investigated the prognostic value of SII in patients with RCC.MethodsWe systematically searched English articles in the PubMed, Embase, Web of Science, and Cochrane Library databases up to October 2021. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to obtain pooled results.ResultsThe meta-analysis included 10 studies that enrolled 3,180 patients. A high SII was associated with poor overall survival (HR 1.75, 95% CI 1.33–2.30, p<0.001) in patients with RCC. However, a high SII was not shown to be a significant prognostic factor for progression-free survival/disease-free survival (HR 1.22, 95% CI 0.84–1.76, p=0.293) or poor cancer-specific survival (HR 1.46, 95% CI 0.68–3.12, p=0.332) in patients with RCC. A high SII was correlated with male sex (OR 1.51, 95% CI 1.11–2.04, p=0.008), Fuhrman grade G3–G4 (OR 1.80, 95% CI 1.08–3.00, p=0.024), and poor risk based on the International Metastatic Renal Cell Carcinoma Database Consortium criteria (OR 19.12, 95% CI 9.13–40.06, p<0.001).ConclusionA high SII was independently associated with poor survival outcomes in patients with RCC. Additionally, an elevated SII indicated more aggressive disease. The SII may serve as a useful cost-effective prognostic indicator in patients with RCC.

show abstract

Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

Cited by 5 publications

References 41 publications

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Contact Info

Product

Resources

About